The Diet of Higher Insulinemic Potential Is Not Associated with Worse Survival in Patients with Stage III Colon Cancer (Alliance).

Autor:	Cheng E; Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut., Zhang S; Division of Medical Oncology, Dana-Farber/Partners Cancer Care, Boston, Massachusetts., Ou FS; Alliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota., Mullen B; Alliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota., Ng K; Division of Medical Oncology, Dana-Farber/Partners Cancer Care, Boston, Massachusetts., Saltz LB; Memorial Sloan Kettering Cancer Center, New York, New York., Niedzwiecki D; Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina., Mayer RJ; Division of Medical Oncology, Dana-Farber/Partners Cancer Care, Boston, Massachusetts., Mowat RB; Toledo Community Hospital Oncology Program, Toledo, Ohio., Whittom R; Hôpital du Sacré-Coeur de Montréal, Montreal, Quebec, Canada., Hantel A; Loyola University, Stritch School of Medicine, Naperville, Illinois., Benson A; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois., Atienza D; Virginia Oncology Associates, Norfolk, Virginia., Messino M; Southeast Cancer Oncology Research Consortium, Mission Hospitals, Asheville, North Carolina., Kindler H; University of Chicago, Chicago, Illinois., Giovannucci EL; Department of Epidemiology and Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts., Van Blarigan EL; Department of Epidemiology and Biostatistics and Department of Urology, University of California, San Francisco, California., Meyerhardt JA; Division of Medical Oncology, Dana-Farber/Partners Cancer Care, Boston, Massachusetts., Fuchs CS; Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut. charles.fuchs@yale.edu.; Division of Hematology and Medical Oncology, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.; Yale Cancer Center, New Haven, Connecticut.
Jazyk:	angličtina
Zdroj:	Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology [Cancer Epidemiol Biomarkers Prev] 2020 Aug; Vol. 29 (8), pp. 1692-1695. Date of Electronic Publication: 2020 Jun 04.
DOI:	10.1158/1055-9965.EPI-19-1454
Abstrakt:	Background: Hyperinsulinemia is considered to be important in the development of colon cancer, but few studies have investigated the associations of hyperinsulinemia with colon cancer survival via dietary scores. Methods: Empirical dietary index for hyperinsulinemia (EDIH) was derived to assess the insulinemic potential of daily diets reflecting the long-term insulin exposure, with higher (more positive) scores indicating higher insulinemic diets. We prospectively estimated the HRs and 95% confidence intervals (CI) to investigate the association of EDIH with disease-free, recurrence-free, and overall survival among patients with stage III colon cancer (1999-2009) enrolled in a randomized adjuvant chemotherapy trial (CALGB 89803). Results: Of 1,024 patients (median follow-up: 7.3 years), 311 died, 350 had recurrences, and 394 had events for disease-free survival. Compared with patients in the lowest quintile of EDIH, the corresponding HRs of patients in the highest quintile for disease-free survival events, cancer recurrence, and overall mortality were 0.80 (95% CI, 0.56-1.15), 0.76 (95% CI, 0.51-1.11), and 0.77 (95% CI, 0.52-1.14). Conclusions: Higher EDIH was not associated with the risk of colon cancer recurrence or mortality in this population of patients with stage III colon cancer. Impact: EDIH, as a measure of dietary insulinemic potential, may be associated with colon cancer risk but not survival in patients with late-stage colon cancer. (©2020 American Association for Cancer Research.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu